Skip to search formSkip to main contentSkip to account menu

nivolumab

Known as: NIVO 
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
3514 Background: mCRC remains a lethal cancer and immunotherapy in MSS mCRC has yet to show significant activity. In preclinical… 
2018
2018
3013Background: IPI-549 is a potential first-in-class, oral, selective PI3K-γ inhibitor that in preclinical studies reprograms… 
2017
2017
1. Becker PE. Myotonia congenita and syndromes associated with myotonia: clinical-genetic studies of the nondystrophic myotonias… 
2017
2017
gates of foamy histiocytes in the dermis and verrucous acanthosis. Regarding its pathogenesis, it is thought that the epithelial… 
2016
2016
Nivolumab (ONO-4538) is an anti-programmed death-1 specific monoclonal antibody, which has become a standard treatment for… 
Highly Cited
2016
Highly Cited
2016
6 Background: Patients (pts) with GC/GEC often present with A/M disease, which has a poor prognosis, with 1-year survival < 30… 
2016
2016
4501Background: Minimal antitumor activity of existing therapies and the observation of immune dysfunction in bladder cancer have… 
2016
2016
We need to focus on five main areas to make real progress in the treatment of kidney cancer, says Robert J. Motzer. 
Highly Cited
2014
Highly Cited
2014
5012 Background: Nivolumab, a fully human IgG4 programmed death-1 (PD-1) inhibitor antibody, has shown encouraging activity in…